Steroid-resistant Relapse of Autoimmune Pancreatitis with Marked Main Pancreatic Duct Dilatation Mimicking Multifocal Pancreatic Cancer.

Intern MedJan 15, 2026 (epub)
Case ReportGastroenterology

Kenji Hirano, Kanami Kondo, Toshifumi Saito et al.

✦ AI-curated · Sources linked

Case in brief

A 67-year-old man with type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis relapsed with pancreatic head swelling and distal bile duct stenosis. The disease worsened despite increasing prednisolone from 7.5 to 20 mg/day. Imaging showed marked main pancreatic duct dilatation (8 mm) and a new pancreatic tail duct stenosis, raising concern for multifocal pancreatic cancer. Repeated endoscopic ultrasound-guided fine-needle aspiration biopsies did not identify malignancy. After prednisolone was increased to 40 mg/day, clinical and radiological findings improved.

What made this case unusual

The relapse produced marked main duct dilatation and a new tail duct stenosis, an appearance that mimicked multifocal pancreatic cancer despite the underlying autoimmune pancreatitis.

Diagnostic / clinical pearl

When autoimmune pancreatitis worsens despite an initial steroid increase and imaging raises concern for cancer, malignancy should be evaluated before further intensifying immunosuppression.

Source

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.